{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:29:57Z","timestamp":1780615797111,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","award":["18)0210"],"award-info":[{"award-number":["18)0210"]}],"id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8226010026"],"award-info":[{"award-number":["8226010026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.wneu.2022.11.056","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T20:56:33Z","timestamp":1668459393000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma"],"prefix":"10.1016","volume":"170","author":[{"given":"Qiqi","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2022.11.056_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2022.11.056_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23551","article-title":"The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma","volume":"88","author":"O'Neill","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.wneu.2022.11.056_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","article-title":"Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors","volume":"80","author":"Jahnke","year":"2006","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2022.11.056_bib4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2022.11.056_bib5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.wneu.2022.11.056_bib6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/neuonc\/noy193","article-title":"Introduction of novel agents in the treatment of primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2022.11.056_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.blre.2016.10.001","article-title":"NF-\u03baB signaling pathway and its potential as a target for therapy in lymphoid neoplasms","volume":"31","author":"Yu","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.wneu.2022.11.056_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","article-title":"Genomic characterization of primary central nervous system lymphoma","volume":"131","author":"Fukumura","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2022.11.056_bib9","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.18632\/oncotarget.2080","article-title":"Mutational analysis of primary central nervous system lymphoma","volume":"5","author":"Bruno","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2022.11.056_bib10","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2008-12-194852","article-title":"TNFAIP3\/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas","volume":"114","author":"Honma","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2022.11.056_bib11","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2022.11.056_bib12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.wneu.2022.11.056_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2022.11.056_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.05.010","article-title":"Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: review of literature and future opportunities","volume":"127","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.wneu.2022.11.056_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2022.11.056_bib16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.wneu.2022.11.056_bib17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.wneu.2022.11.056_bib18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.neo.2018.08.012","article-title":"Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes","volume":"20","author":"Zhou","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.wneu.2022.11.056_bib19","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","article-title":"MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas","volume":"3","author":"Nayyar","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.wneu.2022.11.056_bib20","article-title":"Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients","volume":"27","author":"Barakat","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.wneu.2022.11.056_bib21","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1038\/s41598-020-80376-0","article-title":"Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma","volume":"11","author":"Pedrosa","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.wneu.2022.11.056_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","article-title":"Pathogenetic importance and therapeutic implications of NF-\u03baB in lymphoid malignancies","volume":"246","author":"Lim","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.wneu.2022.11.056_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cas.13450","article-title":"Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma","volume":"109","author":"Hattori","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.wneu.2022.11.056_bib24","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.wneu.2017.12.028","article-title":"MyD88 mutation in elderly predicts poor prognosis in primary central nervous system lymphoma: multi-institutional analysis","volume":"112","author":"Takano","year":"2018","journal-title":"World Neurosurg"},{"key":"10.1016\/j.wneu.2022.11.056_bib25","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/bloodadvances.2021006018","article-title":"A\u00a0genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome","volume":"6","author":"Guney","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.wneu.2022.11.056_bib26","first-page":"vdab090","article-title":"MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: a single-center experience","volume":"3","author":"Curran","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.wneu.2022.11.056_bib27","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.3390\/cancers13246334","article-title":"Impact of a faulty germinal center reaction on the pathogenesis of primary diffuse large B cell lymphoma of the central nervous system","volume":"13","author":"Montesinos-Rongen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.wneu.2022.11.056_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2022.11.056_bib29","first-page":"30","article-title":"[Expression and prognostic value of CARD11 in diffuse large B cell lymphoma]","volume":"37","author":"Zhao","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.wneu.2022.11.056_bib30","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.wneu.2022.11.056_bib31","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1084\/jem.20180230","article-title":"Activated CARD11 accelerates germinal center kinetics, promoting mTORC1 and terminal differentiation","volume":"215","author":"Wray-Dutra","year":"2018","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.wneu.2022.11.056_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.14080","article-title":"MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma","volume":"177","author":"Hattori","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.wneu.2022.11.056_bib33","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B Cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.wneu.2022.11.056_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies","volume":"10","author":"Ondrisova","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.wneu.2022.11.056_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"Soussain","year":"2019","journal-title":"Europ J Cancer"},{"key":"10.1016\/j.wneu.2022.11.056_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2022.11.056_bib37","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.wneu.2022.11.056_bib38","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2018-02-835496","article-title":"Phase 1 study of pomalidomide and dexamethasone for relapsed\/refractory primary CNS or vitreoretinal lymphoma","volume":"132","author":"Tun","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2022.11.056_bib39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2022.11.056_bib40","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"Gonzalez-Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2022.11.056_bib41","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1158\/1078-0432.CCR-13-1551","article-title":"Molecular pathways: CDK4 inhibitors for cancer therapy","volume":"20","author":"Dickson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2022.11.056_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2015.03.001","article-title":"PIM kinase (and Akt) biology and signaling in tumors","volume":"151","author":"Warfel","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.wneu.2022.11.056_bib43","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-05-1465","article-title":"Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation","volume":"103","author":"Montesinos-Rongen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2022.11.056_bib44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11060-018-2990-6","article-title":"Characterization of genomic alterations in primary central nervous system lymphomas","volume":"140","author":"Zorofchian","year":"2018","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2022.11.056_bib45","first-page":"2489","article-title":"The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma","volume":"6","author":"Kuo","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.wneu.2022.11.056_bib46","article-title":"PIM1 and CD79B mutation status impacts the outcome of primary diffuse large B-cell lymphoma of the CNS","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.wneu.2022.11.056_bib47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/med.21284","article-title":"The PIM family of serine\/threonine kinases in cancer","volume":"34","author":"Narlik-Grassow","year":"2014","journal-title":"Med Res Rev"},{"key":"10.1016\/j.wneu.2022.11.056_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100012","article-title":"Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence","volume":"6","author":"Magnes","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.wneu.2022.11.056_bib49","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2019.242701","article-title":"The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma","volume":"106","author":"Montesinos-Rongen","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.wneu.2022.11.056_bib50","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4049\/jimmunol.1402341","article-title":"Primary central nervous system (CNS) lymphoma B cell receptors recognize CNS proteins","volume":"195","author":"Montesinos-Rongen","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.wneu.2022.11.056_bib51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/leu.2014.264","article-title":"The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing","volume":"29","author":"Vater","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.wneu.2022.11.056_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.17319","article-title":"Exome sequencing identifies SLIT2 variants in primary CNS lymphoma","volume":"193","author":"Kaulen","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.wneu.2022.11.056_bib53","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3390\/ijms17050683","article-title":"Gene mutation profiles in primary diffuse large B cell lymphoma of central nervous system: next generation sequencing analyses","volume":"17","author":"Todorovic Balint","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.wneu.2022.11.056_bib54","doi-asserted-by":"crossref","first-page":"27471","DOI":"10.18632\/oncotarget.25463","article-title":"Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma","volume":"9","author":"Takashima","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2022.11.056_bib55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-015-1461-9","article-title":"TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium","volume":"130","author":"Bruno","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2022.11.056_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40478-016-0307-6","article-title":"TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy","volume":"4","author":"Munch-Petersen","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.wneu.2022.11.056_bib57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jns.2004.11.038","article-title":"VH gene analysis of primary CNS lymphomas","volume":"228","author":"Pels","year":"2005","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.wneu.2022.11.056_bib58","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.wneu.2022.11.056_bib59","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1097\/CM9.0000000000000844","article-title":"Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment","volume":"133","author":"Zhang","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.wneu.2022.11.056_bib60","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/path.1783","article-title":"High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis","volume":"206","author":"Riemersma","year":"2005","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.wneu.2022.11.056_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46473-5","article-title":"Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1\/Th-2 status is guaranteed for prognosis prediction in PCNSL","volume":"9","author":"Takashima","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.wneu.2022.11.056_bib62","first-page":"491","article-title":"Immune checkpoint molecules in primary diffuse large B-cell lymphoma of the central nervous system","volume":"11","author":"Monabati","year":"2020","journal-title":"Basic Clin Neurosci"},{"key":"10.1016\/j.wneu.2022.11.056_bib63","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2022.11.056_bib64","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/10428194.2018.1480771","article-title":"Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma","volume":"60","author":"Ambady","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.wneu.2022.11.056_bib65","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1097\/PAS.0000000000000503","article-title":"Primary CNS T-cell lymphomas: a clinical, morphologic, immunophenotypic, and molecular analysis","volume":"39","author":"Menon","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.wneu.2022.11.056_bib66","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/PAS.0000000000001859","article-title":"Clinicopathologic and genetic features of primary T-cell lymphomas of the central nervous system: an analysis of 11 cases using targeted gene sequencing","volume":"46","author":"Yim","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.wneu.2022.11.056_bib67","first-page":"1598","article-title":"The molecular hallmarks of primary and secondary vitreoretinal lymphoma","volume":"6","author":"Bonzheim","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.wneu.2022.11.056_bib68","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood.2020008520","article-title":"EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity","volume":"137","author":"Gandhi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2022.11.056_bib69","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1080\/10428194.2019.1620942","article-title":"Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma","volume":"60","author":"Sethi","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875022016084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875022016084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:15:22Z","timestamp":1761815722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875022016084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":69,"alternative-id":["S1878875022016084"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2022.11.056","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2022.11.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}